Akebia therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass. , aug. 1, 2024 /prnewswire/ -- akebia therapeutics®, inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 47,000 shares of akebia's common stock on july 31, 2024.

NDAQ Ratings Summary

NDAQ Quant Ranking